The shadow of generic rivalry has repeatedly loomed over copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the outlook of connected pharmaceutical ventures. While first years saw substantial gains, the patent lapse has opened the way for less expensive substitutes, potentia